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BACKGROUND Beta-adrenergic blocking agents are the cornerstone in the treatment of coronary artery
disease (CAD). The exact pathophysiologic mechanism is not clear but depends largely on the
oxygen-sparing effect of the drug. Thus, the effect of metoprolol on coronary flow reserve and
coronary flow velocity reserve (CFVR) was determined in patients with CAD.
METHODS Coronary blood flow velocity was measured with the Doppler flow wire in 23 patients (age:
56 10) undergoing percutaneous transluminal coronary angioplasty for therapeutic reasons.
Measurements were carried out at rest, after 1-min vessel occlusion (postischemic CFVR) as
well as after intracoronary adenosine (pharmacologic CFVR) before and after 5 mg
intravenous metoprolol. In a subgroup (n  15), absolute flow was measured from coronary
flow velocity multiplied by coronary cross-sectional area.
RESULTS Rate-pressure product decreased after metoprolol from 9.1 to 8.0  103 mm Hg/min (p 
0.001). Pharmacologic CFVR was 2.1 at rest and increased after metoprolol to 2.7 (p 
0.002). Likewise, postischemic CFVR increased from 2.6 to 3.3 (p  0.001). Postischemic
CFVR was significantly higher than pharmacologic CFVR before as well as after metoprolol.
Coronary vascular resistance decreased after metoprolol from 3.4  2.0 to 2.3  0.7 mm Hg
 s/cm (p  0.02).
CONCLUSIONS The following conclusions were drawn from this study. Metoprolol is associated with a
significant increase in postischemic and pharmacologic CFVR. However, postischemic
CFVR is significantly higher than pharmacologic CFVR. The increase in CFVR by
metoprolol can be explained by a reduction in vascular resistance. The increase in CFVR
( increased supply) and the reduction in oxygen consumption ( decreased demand) after
metoprolol explain the beneficial effect of this beta-blocker in patients with CAD. (J Am
Coll Cardiol 2001;38:1866–71) © 2001 by the American College of Cardiology
The capacity of the coronary arteries to increase flow during
hyperemia by a factor of three to four was described as early
as in 1939 by Katz and Lindner (1). However, it was not
until 1960 that the concept of coronary flow reserve (CFR)
was introduced by Coffman and Gregg (2) to assess the
capacity of coronary circulation to conduct maximal hyper-
emic blood flow. Pharmacologic agents commonly used to
induce maximal vasodilation include papaverine (3–5),
adenosine (4,6) and dipyridamole (4). Hyperemia can also
be induced by transient vessel occlusion (7) or dynamic
exercise (8).
Coronary flow reserve is the ratio of coronary blood flow
during maximal vasodilation divided by resting flow. Be-
cause the pressure-flow relationship is linear and steep
during maximal vasodilation, peak flow is a function of
coronary resistance in the absence of epicardial coronary
artery lesions (9). Therapeutic interventions may affect CFR
by changing resting or maximal flow. A small increase in
resting flow leads, however, to a large decrease in CFR, and
vice versa.
Metoprolol has been shown to reduce oxygen consump-
tion of the myocardium and, thus, diminishes myocardial
ischemia ( reduced demand). However, a preliminary
report using positron emission tomography in healthy
volunteers for coronary flow measurements also indicated
an improvement in CFR after beta-adrenergic blockade
( increased supply), which was mainly due to an increase
in hyperemic flow rather then a decrease in resting flow
(10). Thus, the purpose of this study was to assess the effect
of intravenous metoprolol on CFR, respectively, coronary
flow velocity reserve (CFVR) in patients with coronary
artery disease (CAD) using adenosine and postischemic
hyperemia as stimulus for maximal flow increase.
METHODS
Patients. Twenty-three patients (age: 58  10 years, all
men) with one- (n  17) or two-vessel (n  6) disease are
included in this analysis. Three of the 23 patients had
previous myocardial infarction, but none of these patients
had a Q-wave infarct (Table 1). All patients underwent
percutaneous transluminal coronary angioplasty (PTCA) for
clinical purposes (angina pectoris or positive exercise test
with ST-segment depression). Patients with diffused or
three-vessel disease were excluded from this analysis.
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Coronary angiography. Patients underwent left heart
catheterization for diagnostic purposes. Aortic and left
ventricular pressure were measured with a pigtail catheter.
Biplane left ventricular angiography was performed at the
end of diagnostic coronary angiography. Coronary artery
lesions were assessed quantitatively as percent diameter
stenosis. Vessel diameter at the tip of the flow wire was
measured by quantitative coronary angiography (QCA)
using the ACA package on Philips DC/Integris system.
Collateralization was assessed according to the Rentrop
classification (11).
Doppler flow velocity measurements. Doppler flow veloc-
ity was measured with a 0.014 in. Doppler guide wire with a
12-MHz piezoelectric crystal at its tip (FloWire, EndoSonics,
Rancho Cordova, California). The validation of this Doppler
guide wire has been described previously (12).
Coronary flow velocity reserve was calculated from hyper-
emic peak flow velocity averaged over two cardiac cycles
(averaged peak velocity  APV, cm/s) divided by resting flow
velocity (Fig. 1). Pharmacologic CFVR was induced by an
intracoronary bolus of 18 g adenosine for the left and 12 g
for the right coronary artery (13). Postischemic hyperemia was
induced by a 1-min balloon occlusion. Coronary vascular
resistance was calculated from mean aortic pressure divided by
mean coronary flow velocity (mm Hg  s/cm).
In a subgroup of 15 patients, coronary flow was calculated
from coronary flow velocity multiplied by coronary artery
dimension at the tip of the flow wire measured by QCA 
0.3. From these measurements CFR was determined.
Recent data (14,15) indicate that the standard (13) adeno-
sine dose (18 g for the left and 12 g for the right coronary
artery) may be submaximal in some patients. Therefore, in a
group of six patients, the effect of two different adenosine doses
(18 and 24 g) on coronary flow reserve was tested.
Study protocol. The following study protocol were ad-
hered to:
1. Diagnostic angiography
2. Intracoronary bolus of nitroglycerin (0.2 mg, repeated
every 5 to 10 min)
3. PTCA
4. Control studies
a. Rest measurements 1
b. Measurements during hyperemia (adenosine, intra-
coronary [i.c.])
c. Rest measurements 2
d. Measurements during hyperemia (1-min coronary
occlusion)
5. Administration of 5 mg metoprolol, intravenous
a. Rest measurements 1
b. Measurements during hyperemia (adenosine, i.c.)
c. Rest measurements 2
d. Measurements during hyperemia (1-min coronary
occlusion).
The present study protocol was approved by the local
ethics committee, and all patients gave informed consent.
Statistical analysis. Comparison of angiographic, hemody-
mamic and Doppler flow velocity data was performed by an
unpaired two-sided Student t test. A two-way analysis of
variance for repeated measurements was performed for
comparison of hemodynamic and Doppler flow data. Cor-
relation between CFVR and CFR (n  15) was performed
using the square method. The correlation coefficient (r) and
the regression equation were calculated from these data.
Statistical significance was defined at a p value of 0.05.
RESULTS
Average number of diseased vessel was 1.3 per patient. No
collateral flow was observed in the majority of patients (n 
18). However, in five patients there was mild collateral flow
(grade 1) according to Rentrop classification (16).
Hemodynamics. There was a significant decrease in heart
rate after metoprolol administration (Table 2, Fig. 2).
Mean aortic pressure also dropped significantly after metopro-
lol, but this difference was lost during adenosine infusion.
Consecutively, the rate-pressure product decreased signifi-
cantly.
Abbreviations and Acronyms
CAD  coronary artery disease
CFR  coronary flow reserve
CFVR  coronary flow velocity reserve
i.c.  intracoronary
PTCA  percutaneous transluminal coronary angioplasty
QCA  quantitative coronary angiography
Table 1. Patient Characteristics
n %
Number of patients 23 —
Age (yr) 56  10 —
Men 22 96
Cardiovascular risk factors
Smoking 11 48
Diabetes mellitus 4 17
Family history of CAD 5 22
Obesity 3 13
Hypertension 10 43
Hypercholesterolemia 6 26
Medication
Aspirin 19 83
Beta-blockers 0 0
Calcium antagonists 3 13
Lipid lowering agents 3 13
ACE inhibitors 7 30
Nitrates 8 35
Vessel studied
LAD/LCX/RCA 12/4/7 52/17/30
% Diameter stenosis
Pre-PTCA 83  10
Post-PTCA 6  8
ACE  angiotensin-converting enzyme; CAD  coronary artery disease; LAD 
left anterior descending coronary artery; LCX  left circumflex coronary artery;
PTCA  percutaneous transluminal angioplasty; RCA  right coronary artery.
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Coronary flow velocity and flow reserve. Basal coronary
flow velocity remained unchanged after 5 mg metoprolol
but increased significantly (147%) during adenosine infu-
sion after beta-blockade than after adenosine infusion alone
(94%; p  0.001) (Table 2, Fig. 3). Conversely, the post-
ischemic flow increase was significantly larger (219%) after
metoprolol than it was after ischemia alone (153%; p 
0.005). Maximal flow velocity was significantly higher after
metoprolol for both pharmacologic and postischemic vasodi-
lation.
Similarly, both pharmacologic and postischemic CFVR
increased significantly from 2.1  0.6 to 2.6  0.9, respec-
tively, to 2.7  0.8 to 3.3  1.0 after intravenous admin-
istration of 5 mg metoprolol (Fig. 3). In two patients there was
no change in pharmacologic CFVR, and in two patients
CFVR even decreased after beta-blockade. Postischemic
CFVR was significantly higher than pharmacologic CFVR.
In a subgroup of 15 patients, coronary cross-sectional area
did not change significantly after 5 mg metoprolol (baseline:
6.5  0.7 mm2; after beta-blockade: 6.4  0.5 mm2; p 
NS). Therefore, basal flow velocity and volumetric flow
remained unchanged after metoprolol. In these patients
CFR data were comparable to CFVR data.
The effect of 18 g and 24 g adenosine was studied in
a group of six patients with normal coronary arteries. There
Figure 1. Representative recordings of coronary flow velocity signal in a patient with single-vessel disease undergoing percutaneous transluminal coronary
angioplasty. The tracings are shown in the panels from top to bottom: electrocardiogram, aortic pressure, instantaneous flow velocity and flow velocity
trend. Pharmacologic coronary flow velocity reserve (CFVR) (left): flow velocity at rest  9.1 cm/s, maximal flow velocity after administration of 18 g
adenosine  28 cm/s; CFVR: 28/9.1  3.1. Determination of postischemic CFVR (right): flow velocity after 1-min balloon occlusion  28 cm/s; CFVR:
28/9.1  3.1. Pharmacologic CFVR after metoprolol (lower panels): flow velocity at rest  9.7 cm/s, maximal flow velocity after adenosine  36 cm/s;
CFVR: 36/9.7  3.7. Postischemic CFVR: postischemic flow velocity  41 cm/s; CFVR: 41/9.7  4.2.
Table 2. Hemodynamics
Control Metoprolol p Value
Coronary flow velocity reserve
Pharmacologic 2.1  0.6 2.6  0.9  0.001
Postischemic 2.7  0.8 3.3  0.9  0.005
Coronary flow reserve (n  15)
Pharmacologic 1.8  0.5 2.6  0.9  0.001
Postischemic 2.5  0.8 3.2  0.9  0.05
Heart rate (beats/min)
Rest 74  10 70  7  0.01
Adenosine 76  9 70  6  0.001
Ischemia 77  7 68  7  0.0001
Mean aortic pressure (mm Hg)
Rest 96  13 92  11  0.01
Adenosine 91  12 88  12 NS
Ischemia 94  13 89  13  0.002
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was no further flow increase with the higher adenosine dose
(24 g) than with the reported standard dose (18 g).
Coronary flow reserve in these patients was 2.99  0.64
with 18 g and 3.03  0.73 with 24 g (n  23, n  NS).
Coronary vascular resistance. Coronary vascular resis-
tance was slightly lower (n  NS) after metoprolol but
significantly lower during pharmacologic, respectively, post-
ischemic hyperemia (Fig. 4). Metoprolol further enhanced
the drop in vascular resistance with pharmacologic, respec-
tively, postischemic vasodilation (Fig. 4).
DISCUSSION
Changes in coronary hemodynamics associated with the
administration of beta-blockers have been extensively
studied in the past. Animal experiments have shown a
reduction in coronary blood flow at rest, which has been
explained by coronary vasoconstriction (17–19). Previous
clinical data using coronary flow measurements suggest that
beta-blockers lead to enhanced coronary vascular resistance
during hyperemia due to unopposed alpha-adrenergic vaso-
motor tone (20). However, this study was performed using
a nonselective beta-blocker, and only five of nine patients
showed an increase of hyperemic coronary vascular resis-
tance after propranolol, whereas, in four patients, coronary
flow behaved similarly to our study. In part, this variability
may have been related to the less precise method of flow
determination by coronary sinus thermodilution. In 10
healthy volunteers, Boettcher and coworkers (10) have
reported an increase in CFR after 50 mg oral metoprolol.
Absolute coronary flow was measured noninvasively by
positron emission tomography. The increase in CFR was
achieved by a significant increase in maximal coronary flow,
which was enhanced by a significant decrease in resting
flow. In this study in patients with CAD, pharmacologically
induced and postischemic flow velocity reserve increased
after intravenous administration of 5 mg metoprolol due to
an increase in maximal flow (Table 3, Fig. 3). At the same
time, coronary vascular resistance decreased after beta-
blockade but only during maximal vasodilation and not at
rest (Fig. 4). The reduction in coronary vascular resistance
can be explained by a diminution of the extravascular
compressive forces either due to a reduced filling pressure or
a decrease in myocardial contractility with a reduction in
vascular tone. Comparison of the two vasodilatory stimuli,
that is, pharmacologic vasodilation with adenosine versus
postischemic vasodilation by 1-min balloon occlusion,
clearly showed a stronger effect (Fig. 3) with ischemia. This
can be either due to the duration and severity of the
Figure 2. Rate-pressure product: before (left) and after (right) 5 mg
metoprolol, intravenous, at rest as well as during hyperemia. There is a
significant reduction in the rate-pressure product after beta-blockade.
ADO  adenosine.
Figure 3. Pharmacologic and postischemic coronary flow velocity reserve
(CFVR) increased significantly from 2.1  0.6 to 2.6  0.9, respectively,
from 2.7  0.8 to 3.3  1.0 after intravenous administration of 5 mg
metoprolol. In two patients, there was no change in pharmacologic CFVR,
but in another two patients there was even a decrease in CFVR after
beta-blockade. Postischemic CFVR was generally higher than pharmaco-
logic CFVR.
Figure 4. Coronary vascular resistance was slightly lower (NS) after
metoprolol but significantly lower during pharmacologic, respectively,
postischemic vasodilation. ADO  adenosine.
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ischemic event or the dose of adenosine. Since no additional
effect on CFR was observed with a higher (24 g) than
standard (18 g) dose of adenosine, pharmacologic vasodi-
lation was maximal with the standard dose used in this
study.
Study limitations. Several limitations have to be consid-
ered for this article:
1) Changes in heart rate and mean aortic pressure may
affect coronary flow velocity. Metoprolol decreases heart
rate and aortic pressure, which might reduce coronary
flow velocity. However, despite the decrease in heart rate
and mean aortic pressure (Table 2), resting coronary flow
velocity did not change in this study. Therefore, these
effects seem to be of minor importance for the observed
changes in flow velocity. On the other hand, adenosine
as a strong vasodilator may lead to a drop in pressure
and, thus, may decrease CFR. This was not the case in
this analysis. Furthermore, all patients received the same
dose at the same time of the study protocol.
2) The standard adenosine dose used for maximal hyper-
emia was 12 g for the right and 18 g for the left
coronary artery. Recent data (14,15) suggest that these
doses may be submaximal in some patients and, thus,
may lead to an underestimation of CFR. This could
explain why postischemic hyperemia might give higher
CFR values than adenosine. Therefore, we measured
CFR in a group of six patients after 18 and 24 g
adenosine, i.c. There was no significant difference in
CFR (2.99 vs. 3.03, p  NS). Thus, the standard
adenosine dose seems to be sufficient to induce maximal
vasodilation in most patients.
3) Coronary flow velocity measurements may be limited by
a change in sampling volume due to the motion of the
flow wire within the coronary tree. We, therefore,
assured that only patients with a stable and good flow
signal were included in this analysis.
4) Changes in coronary artery diameter could, theoretically,
affect flow velocity measurements. Thus, in 15 patients
coronary artery diameter at the tip of the flow wire was
measured, and absolute coronary blood flow was calcu-
lated from flow velocity and coronary cross-sectional
area. Cross-sectional area remained unchanged after
beta-blockade and, thus, did not account for changes in
coronary flow velocity.
5) Cross-sectional area during maximal hyperemia with
adenosine was not measured. However, in a previous
study we have shown that, after intracoronary nitro-
glycerin, coronary dimensions did not change further,
even with an extremely high dose (2.4 mg/min) of
intracoronary adenosine (cross-sectional area before:
7.1  2.6 mm2; during adenosine infusion: 7.2 
2.8 mm2). Thus, cross-sectional area is unchanged dur-
ing adenosine infusion after maximal vasodilation with
nitroglycerin and has no effect on coronary flow velocity.
Conclusions. Metoprolol is associated with a significant
increase in CFR despite a reduction in heart rate and
coronary perfusion pressure. This improvement in flow
reserve is not only seen after pharmacologic vasodilation but
also after postischemic hyperemia. The vasodilator response
was, however, enhanced after myocardial ischemia when
compared with adenosine. Apparently, ischemia seems to be
a stronger vasodilator stimulus than adenosine.
In the daily routine, beta-blockers have a large thera-
peutic indication in the treatment of CAD due to their
anti-ischemic and antiarrhythmic effect. The anti-ischemic
effect of beta-blockers is based on the oxygen sparing
mechanism with a reduction in the rate-pressure product
(Fig. 2). However, the improvement in CFR indicates an
improved oxygen supply due to the enhancement of maxi-
mal vasodilation after metoprolol with a potential reduction
in ischemic events. This dual effect is probably responsible
for an increase in blood supply and a reduction in oxygen
demand rendering beta-blockers an ideal drug for treatment
of CAD.
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